Trends in the epidemiology of depression and comorbidities from 2000 to 2019 in Belgium

Walrave, Roosje; Beerten, Simon Gabriël; Mamouris, Pavlos; Coteur, Kristien; Nuland, Marc Van; Pottelbergh, Gijs Van; Casas, Lidia; Vaes, Bert

doi:10.1186/s12875-022-01769-w

Cited by 11 publications

(8 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The global incidence of depression is over three times that of HF [ 8 ]; hence, the predicted prevalence of comorbid depression and HF will expand considerably over the next several years, as will its economic cost [ 9 ]. When combined, HF and depression double healthcare expenses compared to each condition taken individually [ 10 ].…”

Section: Resultsmentioning

confidence: 99%

Depression in Heart Failure with Reduced Ejection Fraction, an Undervalued Comorbidity: An Up-To-Date Review

Basile,

Parlati,

Paolillo

et al. 2023

Medicina

View full text Add to dashboard Cite

Introduction: Depression is a common and severe comorbidity among individuals with heart failure (HF). Up to a third of all HF patients are depressed, and an even higher proportion have symptoms of depression. Aim: In this review, we evaluate the relationship between HF and depression, explain the pathophysiology and epidemiology of both diseases and their relationship, and highlight novel diagnostic and therapeutic options for HF patients with depression. Materials and Methods: This narrative review involved keyword searches of PubMed and Web of Science. Review search terms included [“Depression” OR “Depres*” OR “major depr*”] AND [“Heart Failure” OR “HF” OR “HFrEF” OR “HFmrEF” OR “HFpEF” OR “HFimpEF”] in all fields. Studies included in the review met the following criteria: (A) published in a peer-reviewed journal; (B) described the impact of depression on HF and vice versa; and (C) were opinion papers, guidelines, case studies, descriptive studies, randomized control trials, prospective studies, retrospective studies, narrative reviews, and systematic reviews. Results: Depression is an emergent HF risk factor and strongly relates with worse clinical outcomes. HF and depression share multiple pathways, including platelet dis-reactivity, neuroendocrine malfunction, inappropriate inflammation, tachi-arrhythmias, and frailty in the social and community setting. Existing HF guidelines urge evaluation of depression in all HF patients, and numerous screening tools are available. Depression is ultimately diagnosed based on DSM-5 criteria. There are both non-pharmaceutical and pharmaceutical treatments for depression. Regarding depressed symptoms, non-pharmaceutical treatments, such as cognitive-behavioral therapy and physical exercise, have shown therapeutic results, under medical supervision and with an effort level adapted to the patient’s physical resources, together with optimal HF treatment. In randomized clinical studies, selective serotonin reuptake inhibitors, the backbone of antidepressant treatment, did not demonstrate advantage over the placebo in patients with HF. New antidepressant medications are currently being studied and could provide a chance to enhance management, treatment, and control of depression in patients with HF. Conclusions: Despite the substantial link between depression and HF, their combination is underdiagnosed and undertreated. Considering the hopeful yet unclear findings of antidepressant trials, further research is required to identify people who may benefit from antidepressant medication. The goal of future research should be a complete approach to the care of these patients, who are anticipated to become a significant medical burden in the future.

show abstract

Section: Resultsmentioning

confidence: 99%

Depression in Heart Failure with Reduced Ejection Fraction, an Undervalued Comorbidity: An Up-To-Date Review

Basile,

Parlati,

Paolillo

et al. 2023

Medicina

View full text Add to dashboard Cite

show abstract

“… 14 , 25 , 31 Furthermore, as stated in a previous article by the same team, this increase might also partly be brought about by a registration effect. 19 This is a form of bias: anxiety could be more likely to be registered now than earlier in the study period for various reasons (for example, more diligent and more frequent coding and registration).…”

Section: Discussionmentioning

confidence: 99%

“…This is in line with previous findings from the same author group concerning depression. 19 Patients presenting with mental health disorders in primary care tend to become more complex over time. However, it is also possible that GPs’ awareness of anxiety might be increased specifically in patients with comorbidities.…”

Section: Discussionmentioning

confidence: 99%

“…For the comorbidities at the moment of diagnosis in incident cases (that is, present the same day as the first anxiety diagnosis) a precompiled list of chronic diseases was used, as in a previous study by the same author group. 19 Chronic kidney disease was assessed by the closest creatinine measurements in the 2 years preceding or following a P74 diagnosis.…”

Section: Methodsmentioning

confidence: 99%

“…present the same day as the first anxiety diagnosis), we used a precompiled list of chronic diseases, as in our previous study. 19 We assessed chronic kidney disease by the closest creatinine measurements in the 2 years preceding or following a P74 diagnosis.…”

Section: Anxiety Comorbidities and Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Trends in the registration of anxiety in Belgian primary care from 2000 to 2021: a registry-based study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Anxiety is frequently encountered in general practice, but figures regarding prevalence and incidence in this healthcare setting remain scarce. Aim: To provide insight in the trends of prevalence and incidence of anxiety in Belgian general practice, as well as the comorbidities and treatment of anxiety in this context. Design and setting: A retrospective cohort study using the INTEGO morbidity registration network, collecting clinical data of over 600.000 patients in Flanders, Belgium. Methods: Trends in age-standardized prevalence and incidence of anxiety from 2000 to 2021, as well as prescriptions in prevalent anxiety cases, were analysed with joinpoint regression. Comorbidity profiles were analysed using the Cochran-Armitage test and the Jonckheere-Terpstra test. Results: During the 22-year study period, we identified 8 451 unique patients with anxiety. The prevalence of anxiety diagnoses rose significantly during this period, from 1.1% in 2000 to 4.8% in 2021. The incidence rate rose from 1.1/1000 patient-years (PY) in 2000 to 9.9/1000 PY in 2021. The average chronic disease count per patient increased significantly during the study period, from 1.5 to 2.3 chronic conditions. The most frequent comorbidities in patients with anxiety were malignancy (20.1%), hypertension (18.2%) and irritable bowel syndrome (13.5%). The proportion of patients treated with psychoactive medication rose from 25.7% to almost 40% over the study period. Conclusion: We found a significantly increasing prevalence and incidence of physician-registered anxiety in our study. Patients with anxiety tend to become more complex, with more comorbidities. Treatment for anxiety in Belgian primary care is very dependent on medication.

show abstract

Wandel von Nutzen und Risiko antidepressiver Pharmakotherapie

Baethge

2024

Nervenarzt

View full text Add to dashboard Cite

ZusammenfassungDie antidepressive Pharmakotherapie durchlief in ihrer Geschichte verschiedene Phasen: Der Euphorie der Anfangsjahre über die medikamentöse Erleichterung depressiver Syndrome folgte ein langer Zeitraum klinischer Erfahrung und intensiver wissenschaftlicher Durchdringung, die zu einer abgewogeneren Perspektive führten. Aktuelle Debatten kreisen um die tatsächliche Effektstärke – gerade in Bezug auf lange Behandlungsdauern –, die Prävention von Suiziden und die Folgen des Absetzens eines Antidepressivums. Die Bewertung der Stoffgruppe, aber oft auch das Nutzen-Schaden-Verhältnis einer individuellen Behandlung verändert sich mit der Zeit. Die Antidepressiva stehen exemplarisch für viele psychiatrische Behandlungen, die – in einem Begriff Hanfried Helmchens – ebenso janusköpfig sind wie die Psychiatrie es als Wissenschaft und als klinisches Fach ganz allgemein ist.

show abstract

Trends in the epidemiology of depression and comorbidities from 2000 to 2019 in Belgium

Cited by 11 publications

References 47 publications

Depression in Heart Failure with Reduced Ejection Fraction, an Undervalued Comorbidity: An Up-To-Date Review

Depression in Heart Failure with Reduced Ejection Fraction, an Undervalued Comorbidity: An Up-To-Date Review

Trends in the registration of anxiety in Belgian primary care from 2000 to 2021: a registry-based study

Wandel von Nutzen und Risiko antidepressiver Pharmakotherapie

Contact Info

Product

Resources

About